Florida Time: Sorting Out The Deadlines For Canadian Imports

The approval of Florida’s plan to import drugs from Canada is an important symbolic milestone for FDA and the drug industry. But making sense of the timeline to actually begin the program is not an easy task.

canada florida time
How long will it take for Canadian drugs to actually get to Florida? • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

The US Food & Drug Administration’s approval of Florida’s plan to import drugs from Canada is clearly an important milestone in the decades-long debate over how to address international pricing disparities for prescription drugs.

The news was also appropriately recognized as not an immediate and significant change in the US market, particularly since –...

More from Pricing Debate

How Could MFN Pricing Impact Commercial Market?

 
• By 

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By 

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.

Trump Administration Closer to Unprecedented Drug Price Transparency Requirements

 
• By 

New rules requiring more granular drug pricing data to be disclosed in machine-readable files will go into effect in 2026.

Orphan Drug Relief Still In Budget Bill But Uncertainty Remains

 
• By 

The budget reconciliation bill nears final passage without pharmacy benefit manager reforms or provisions that would facilitate access to cell and gene therapies for children, but its Medicaid cuts pose a significant threat to prescription drug access.

More from Market Access

Orphan Drug Relief Still In Budget Bill But Uncertainty Remains

 
• By 

The budget reconciliation bill nears final passage without pharmacy benefit manager reforms or provisions that would facilitate access to cell and gene therapies for children, but its Medicaid cuts pose a significant threat to prescription drug access.

No ‘Doomsday’ For US Pharma Despite Political Uncertainties, EU Industry Chief Says

 

While challenges in the US present an “incredible opportunity” for Europe, there is no “doomsday” happening there, Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says.

Oz Says Big PBMs Have ‘Window’ to Quit Rebate System on Their Own

 
• By 

CMS Administrator Mehmet Oz said PBMs may deserve "one last chance" to fix the rebate system before federal regulations and legislation are enacted.